论文部分内容阅读
丙硫咪唑是一种具有广谱抗蠕虫性能的苯并咪唑衍生物。最初在法国的158例患者中用该药进行了摸索治疗剂量的预初试验。1980年4月在法国和西非用双盲试验安慰剂对照法治疗392例。1981年4月起在西非扩大临床试验,又治疗各种肠蠕虫病人895例,并在52例蛲虫病患者中与噻嘧啶作比较。本文总结了应用丙硫咪唑治疗上述共1,497例病人的抗虫谱、疗效和副作用。先在预初试验中用丙硫咪唑单次或多次剂量试治线虫、绦虫和吸虫病病人。患者在治前和治后72小时内分别进行全面的体检、血液学和临床血液化学检验以及尿化验等,以评价病人对药物的耐受性。根据预初试验
Albendazole is a benzimidazole derivative with broad-spectrum anthelmintic properties. Initially 158 patients in France with the drug to explore the initial dose of treatment trial. In April 1980, 392 patients were treated in a double-blind placebo-controlled trial in France and West Africa. Since April 1981, clinical trials have been expanded in West Africa, treating 895 patients with various intestinal worms and comparing them to pyrimethamine in 52 patients with enterobiasis. This article summarizes the anti-insect spectrum, efficacy, and side effects of albendazole in a total of 1,497 patients. First in the initial test with albendazole single or multiple doses of test nematodes, tapeworms and fluke patients. Patients in the pre-treatment and post-treatment within 72 hours a comprehensive physical examination, hematology and clinical blood chemistry and urine tests, etc., to evaluate the patient’s tolerance to drugs. According to the preliminary test